Oncolytics Biotech Investor Presentation June 2023

Oncolytics Biotech presents its pipeline focused on pelareorep, an intravenously-delivered immunotherapy designed to make tumors more susceptible to oncology treatments. The presentation outlines the company's clinical development strategy, including potential combination therapies with checkpoint inhibitors and CAR T cell approaches in solid tumors, with advancement toward registrational studies in metastatic breast and pancreatic cancer.